2016
December 5, 2016
Apogenix Reports Final Phase I MDS Data at this Year's American Society of Hematology (ASH) Meeting
November 4, 2016
Apogenix Reports Significant Progress in Collaboration with CANbridge
November 3, 2016
Apogenix Announces Oral Presentation on APG101 at Upcoming 58th American Society of Hematology (ASH) Meeting & Exposition
July 19, 2016
Apogenix Granted European Patent for the Use of APG101 in the Treatment of Myelodysplastic Syndromes
June 15, 2016
Apogenix Reports Topline Results from Phase I Trial in Myelodysplastic Syndromes with APG101
May 4, 2016
Apogenix to Present at Two Upcoming International Conferences
March 24, 2016
Preclinical Efficacy Data of Apogenix' APG101 in Myelodysplastic Syndromes (MDS) published in Oncotarget
February 16, 2016
Apogenix Receives €3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101
January 14, 2016
Apogenix Strengthens U.S. Patent Position for Lead Immuno-Oncology Candidate APG101
January 7, 2016
Apogenix Receives First Milestone Payment from CANbridge Licensing Agreement and Signs Amendment to Include Taiwan
2015
December 15, 2015
Apogenix to Present at J.P. Morgan Healthcare Conference
October 13, 2015
Apogenix to Present at Three Upcoming International Conferences
July 28, 2015
Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101
July 15, 2015
Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China
June 3, 2015
Apogenix appoints Peter Willinger as new CFO
June 1, 2015
Apogenix to present at Jefferies 2015 Global Healthcare Conference
2014
October 28, 2014
Apogenix – Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research
January 13, 2014
Apogenix' APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma
January 7, 2014
Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco
2013
December 5, 2013
Apogenix' APG350 Effectively Induces Apoptosis of Tumor Cells via TRAIL Pathway Independent of Fcγ Cross-Linking
July 2, 2013
Apogenix Strengthens Patent Position for Apocept™ (APG101) in Europe and Canada
February 7, 2013
Apogenix Receives FDA Orphan Drug Designation for Apocept™ to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study
2012
November 6, 2012
Apogenix’s Apocept™ for Glioblastoma Multiforme Named One of “Top 10 Projects to Watch”
July 26, 2012
Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial in Treatment of Recurrent Glioblastoma
May 29, 2012
Apogenix to Present Positive Phase II Results of APG101 in Glioblastoma Multiforme at ASCO
March 8, 2012
Apogenix Announces that APG101 Meets Primary Endpoint in a
Controlled Phase II Trial with Glioblastoma Patients
January 5, 2012
Apogenix Raises € 7.5 Million to Further Advance APG101 to Treat Glioblastoma and other Tumors
January 3, 2012
Apogenix Receives Additional € 2.3 Million BMBF Grant as Partner of the Biotech Cluster Rhine-Neckar
2011
September 20, 2011
Apogenix Successfully Completes Patient Recruitment for Glioblastoma Phase II Trial with APG101
January 24, 2011
Apogenix provides update in the ongoing Phase II clinical trial of APG101 to treat Glioblastoma
2010
May 27, 2010
Data Published in “Nature” Confirms Development of APG101 to Treat Cancer
January 11, 2010
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma
2009
November 16, 2009
Apogenix Receives Orphan Drug Designation for APG101 in the US and Positive Opinion on Orphan Product Designation in Europe
October 27, 2009
Apogenix Significantly Strengthens IP Protection for its Clinical Lead Compound APG101
July 29, 2009
Apogenix Receives Research Grants of EUR 2.6 Million as Partner of the Biotechnology Cluster Rhine-Neckar
May 13, 2009
Apogenix Reports Positive Phase I Results on its Lead Compound AGP101
2008
October 7, 2008
Apogenix Starts Phase I With its Lead Compound AGP101
September 19, 2008
Two Grants Totaling EUR 1.65 million by the German Federal Ministry of Education and Research (BMBF) to Support Apogenix ́ Research
April 30, 2008
Apogenix Raises EUR 27.5m in Series B Financing Round
March, 10, 2008
Publication in Cancer Cell Supports Therapeutic Potential of APG101 in Glioblastoma – New indication for lead compound of Apogenix
2007
October 10, 2007
New Publication Underlines Huge Potential of Apogenix ́ Compounds to Efficiently Eliminate Human Cancer Stem Cells
March 12, 2007
BMBF Grants 1.5m Euro to Further Evaluate the Therapeutic Potential of Apogenix' Lead Product APG101
2006
September 15, 2006
Apogenix receives positive opinion on orphan medicinal product designation from the European Medicines Agency for APG101, for prevention of Graft-versus-Host Disease